NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board

NEOGENOMICS INC

Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.
Dr. Green is SVP and Head of Oncology, Global Clinical Development at Merck, leading oncology R&D for Merck's largest revenue area.
Prior leadership roles include SVP Late-Stage Development at Seagen and VP at Genentech; began career as medical oncologist at MD Anderson.
She will serve as an independent director until the 2026 annual meeting; compensation follows standard director program.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marjorie C. Green

Director

NEO · NEOGENOMICS INC

Effective: 2025-06-19
Filed: Jun 24, 2025 23:59 UTC

On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.

Source: SEC EDGAR

accession 0001077183-25-000145

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.